用于评估未治疗颅内脑膜瘤快速生长风险的新型加权评分系统
该研究回顾性分析了1997至2013年前瞻性随访、未接受治疗的232例推测颅内脑膜瘤患者,用回归分析确定快速生长(≥2 cm3/年)的预测因素并据此赋分,建立AIMSS加权评分系统;59个肿瘤(25.4%)出现快速生长,评分0-2分、3-6分、7-11分对应的快速生长风险分别为<10%、10%-50%、≥50%,ROC曲线下面积为0.86。
要点
- 快速生长预测因素包括肿瘤大小、无钙化、瘤周水肿及T2加权MRI高信号或等信号。
- AIMSS总分0-2分、3-6分、7-11分的快速生长风险分别估计为<10%、10%-50%、≥50%。
- 作者认为AIMSS可预测未治疗颅内脑膜瘤快速生长的具体概率,有助于临床治疗决策。
核心结论
- 作者提出加权评分系统AIMSS,可预测未治疗颅内脑膜瘤患者快速生长的具体概率,通过筛出快速生长高风险患者来辅助临床治疗决策。
研究设计与样本
- 回顾性分析1997至2013年前瞻性随访、未接受治疗的232例推测颅内脑膜瘤患者;随访时以影像测量肿瘤体积,以回归分析确定生长速率,用逻辑回归模型识别快速生长(定义为≥2 cm3/年)的预测因素,并按各因素自身系数值赋分。
主要发现
- 59个肿瘤(25.4%)出现快速生长;肿瘤大小(每cm3 OR 1.07,p=0.000)、无钙化(OR 3.87,p=0.004)、瘤周水肿(OR 2.74,p=0.025)、T2加权MRI高信号或等信号(OR 3.76,p=0.049)为肿瘤生长速率的预测因素。
- AIMSS中肿瘤大小按直径分为<2.5 cm、≥2.5至<4.0 cm、≥4.0 cm三组,分别赋0、3、6分;钙化按有无赋0或2分,瘤周水肿按有无赋1或0分;T2加权MRI信号分为低信号与高信号/等信号两组,分别赋0或2分。
- 总分0-2分时快速生长风险估计为<10%,总分3-6分时为10%-50%,总分7-11分时为≥50%(Hosmer-Lemeshow拟合优度检验,p=0.9958);受试者工作特征曲线下面积为0.86。
关键数值与推荐
- 快速生长定义为≥2 cm3/年;AIMSS总分0-2分、3-6分、7-11分对应的快速生长风险分别估计为<10%、10%-50%、≥50%。
- Hosmer-Lemeshow拟合优度检验p=0.9958,受试者工作特征曲线下面积为0.86。
临床怎么用
- 作者建议使用加权评分系统AIMSS预测未治疗颅内脑膜瘤患者快速生长的具体概率,通过筛出快速生长高风险患者来辅助临床治疗决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE Advances in neuroimaging techniques have led to the increased detection of asymptomatic intracranial meningiomas (IMs). Despite several studies on the natural history of IMs, a comprehensive evaluation method for estimating the growth potential of these tumors, based on the relative weight of each risk factor, has not been developed. The aim of this study was to develop a weighted scoring system that estimates the risk of rapid tumor growth to aid treatment decision making. METHODS The authors performed a retrospective analysis of 232 patients with presumed IM who had been prospectively followed up in the absence of treatment from 1997 to 2013. Tumor volume was measured by imaging at each follow-up visit, and the growth rate was determined by regression analysis. Predictors of rapid tumor growth (defined as ≥ 2 cm3/year) were identified using a logistic regression model; each factor was awarded a score based on its own coefficient value. The probability (P) of rapid tumor growth was estimated using the following formula:[Formula: see text] RESULTS Fifty-nine tumors (25.4%) showed rapid growth. Tumor size (OR per cm3 1.07, p = 0.000), absence of calcification (OR 3.87, p = 0.004), peritumoral edema (OR 2.74, p = 0.025), and hyperintense or isointense signal on T2-weighted MRI (OR 3.76, p = 0.049) were predictors of tumor growth rate. In the Asan Intracranial Meningioma Scoring System (AIMSS), tumor size was categorized into 3 groups of < 2.5 cm, ≥ 2.5 to < 4.0 cm, and ≥ 4.0 cm in diameter and awarded a score of 0, 3, and 6, respectively; the parameters of calcification and peritumoral edema were categorized into 2 groups based on their presence or absence and given a score of 0 or 2 and 1 or 0, respectively; and the signal on T2-weighted MRI was categorized into 2 groups of hypointense and hyperintense/isointense and given a score of 0 or 2, respectively. The risk of rapid tumor growth was estimated to be < 10% when the total score was 0-2, 10%-50% when the total score was 3-6, and ≥ 50% when the total score was 7-11 (Hosmer-Lemeshow goodness-of-fit test, p = 0.9958). The area under the receiver operating characteristic curve was 0.86. CONCLUSIONS The authors suggest a weighted scoring system (AIMSS) that predicts the specific probability of rapid tumor growth for patients with untreated IM. This scoring system will aid treatment decision making in clinical settings by screening out patients at high risk for rapid tumor growth.
引用
- Lee EJ, Kim JH, Park ES, et al. A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. J Neurosurg. 2017. PMID: 28084908. doi:10.3171/2016.9.JNS161669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。